XORTX Therapeutics Secures Funding Through Direct Offering
XORTX Therapeutics Inc. (NASDAQ: XRTX), a clinical-stage pharmaceutical entity, has successfully closed a registered direct offering, raising approximately $1.1 million. This funding, achieved through the sale of 1,750,000 common shares at $0.63 each, marks a significant step in supporting the company's mission to develop innovative treatments aimed at managing gout and progressive kidney disease.
Details of the Offering
The direct offering, which involved an agreement with an institutional investor, concluded with the issuance of 572,470 common shares and 1,117,530 pre-funded warrants. Each warrant allows for the acquisition of an additional common share at an exercise price of $0.001.
Financial Intentions
The gross proceeds amounting to $1,102,500 will be used by XORTX to bolster working capital and cover general corporate expenses. These funds are crucial as the company strives to enhance its research and development efforts.
Role of Placement Agent
D. Boral Capital LLC has served as the sole placement agent for this offering, receiving 87,500 agent warrants in return. These warrants can also be exercised to acquire common shares at an exercise price of $0.69, beginning 181 days after issuance with a term extending for eighteen months.
Understanding the Registration Process
The common shares and pre-funded warrants were issued according to an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC). The registration significantly streamlines the process of issuing shares when capital needs arise.
Innovative Product Pipeline
XORTX holds a promising portfolio with several products in various stages of development. Their lead product, XRx-026, targets gout treatment, while XRx-008 addresses autosomal dominant polycystic kidney disease (ADPKD). Another innovative therapy, XRx-101, focuses on acute kidney injury and other organ damages potentially resulting from virus infections.
Upcoming Projects and Future Prospects
Additionally, the company is developing XRx-225, which is in pre-clinical stages, designed to tackle Type 2 diabetic nephropathy. XORTX Therapeutics concentrates on addressing significant health issues linked to abnormal purine metabolism and xanthine oxidase activity, which are pivotal in the production of uric acid.
Commitment to Patient Care
At XORTX, the primary goal remains to improve the quality of life for patients suffering from gout and other related diseases. Their dedicated research aims at introducing medications that not only alleviate symptoms but also target the underlying metabolic dysfunctions.
Contact Information
For those interested in further details about XORTX Therapeutics, they can reach out to Allen Davidoff, CEO, at adavidoff@xortx.com or call +1 403 455 7727. Alternatively, inquiries can be directed to Nick Rigopulos, the Director of Communications, via email at nick@alpineequityadv.com or on +1 617 901 0785.
Frequently Asked Questions
What type of company is XORTX Therapeutics?
XORTX Therapeutics Inc. is a clinical-stage pharmaceutical company focusing on innovative therapies for gout and kidney diseases.
How much funding did XORTX raise?
XORTX raised approximately $1.1 million through a registered direct offering.
What will the raised funds be used for?
The funds will be allocated to working capital and general corporate purposes.
What products are currently developed by XORTX?
XORTX is developing several products, including those for gout, ADPKD, and acute kidney injury treatment.
Who should be contacted for more information?
Contact Allen Davidoff at adavidoff@xortx.com or Nick Rigopulos at nick@alpineequityadv.com for more inquiries.
